1. Home
  2. RKTO vs CNSY Comparison

RKTO vs CNSY Comparison

Compare RKTO & CNSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocket One Inc. Common Stock

RKTO

Rocket One Inc. Common Stock

HOLD

Current Price

$0.53

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

Logo Cerenome Inc. Common Stock

CNSY

Cerenome Inc. Common Stock

N/A

Current Price

$1.76

Market Cap

20.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RKTO
CNSY
Founded
2017
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9M
20.6M
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
RKTO
CNSY
Price
$0.53
$1.76
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $27.75
AVG Volume (30 Days)
★ 247.2K
162.6K
Earning Date
11-11-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
29.69
★ 87.61
EPS
★ N/A
N/A
Revenue
N/A
★ $5,213,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$414.61
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.48
$1.49
52 Week High
$1.19
$4.03

Technical Indicators

Market Signals
Indicator
RKTO
CNSY
Relative Strength Index (RSI) 32.20 41.45
Support Level N/A $1.52
Resistance Level $0.77 $1.96
Average True Range (ATR) 0.05 0.17
MACD -0.01 0.04
Stochastic Oscillator 17.19 55.81

Price Performance

Historical Comparison
RKTO
CNSY

About RKTO Rocket One Inc. Common Stock

Rocket One Inc is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The company also intends to pursue opportunities related to nano-launch systems and nanosatellite deployment. In addition, its biotechnology operations, conducted through a wholly owned subsidiary, include development programs such as HT-001, HT-KIT, HT-ALZ, and a GDNF-based metabolic program.

About CNSY Cerenome Inc. Common Stock

Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.

Share on Social Networks: